Pharma BD Deal Intelligence

Endo Health Solutions Inc. / NuPathe Inc.

2013 · Acquisition/Merger · $271M · Terminated

Endo announced agreement to acquire NuPathe at $2.85/share cash (~$105M) + CVR up to $3.15/share (~$116M) tied to Zecuity sales. Endo deal terminated Jan 2014 in favor of Teva's superior $144M offer ($3.65/share).

Key facts

• Announced Dec 16, 2013
• Deal value $271M
• Deal type Acquisition/Merger
• Therapeutic area Acute migraine in adults
• Indications Acute migraine in adults
• Key assets Zecuity (sumatriptan iontophoretic transdermal patch)
• Mechanism Iontophoretic transdermal sumatriptan delivery (5-HT1B/1D agonist)

← Browse all deals  ·  How we score deals